Skip to main content

Table 4 Use of SGLT2-inhibitors or GLP1 receptors agonists

From: Clinical utility of a novel test for assessing cardiovascular disease risk in type 2 diabetes: a randomized controlled trial

 

Round 1

Round 2

p-value

SGLT2i/GLP1 RA

 Control

35.4%

45.0%

0.082

 Int 1

38.4%

66.9%

< 0.001

 Int 2

43.3%

72.3%

< 0.001

 p-value

0.359

< 0.001

 
  1. SGLT2i sodium–glucose cotransporter-2 inhibitors, GLP1 RA glucagon-like peptide-1 receptor agonists
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us